ABSTRACT
No disponible
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Outcome and Process Assessment, Health Care , Home Care Services, Hospital-Based , Mental Disorders/therapy , Suicide, Attempted , Socioeconomic Factors , SpainABSTRACT
Introducción: A pesar del desarrollo de la hospitalización domiciliaria en España durante los últimos años, es llamativa la escasez de literatura. El siguiente estudio pretende exponer los datos obtenidos por la Unidad de Hospitalización a Domicilio de Psiquiatría del Hospital del Mar (HADMar). HADMar es un programa de hospitalización domiciliaria creado hace 2años, que recibe pacientes procedentes de servicios comunitarios y hospitalarios con un seguimiento limitado en el tiempo. Al alta, el paciente es derivado a la unidad de referencia ambulatoria apropiada para cada caso. Material y métodos: Se seleccionó a todos los pacientes visitados desde 2015 hasta la actualidad. Se llevó a cabo un estudio descriptivo que define las características sociodemográficas de la muestra. Las variables clínicas estudiadas fueron la gravedad de los síntomas, el riesgo de suicidio y los cambios en la funcionalidad. Resultados: Un total de 135 pacientes fueron incluidos en la muestra. La edad media de los pacientes fue de 44,6 años y no hubo diferencias entre ambos sexos. De ellos, 26 pacientes tenían un historial de intentos autolíticos y el 11,1% vivían solos. El 51,1% fueron diagnosticados de un trastorno psicótico. La puntuación media en la escala GEP en la variable gravedad de los síntomas psiquiátricos fue 2,39 y el riesgo medio de suicidio 0,49. La puntuación de EEAG al alta era mayor que al ingreso. Conclusiones: Los resultados obtenidos en nuestro estudio son consistentes con resultados reportados en estudios previos. Los equipos de hospitalización domiciliaria han demostrado ser una alternativa a la hospitalización tradicional. Sin embargo, se necesitan más estudios que apoyen estos resultados
Introduction: Although home hospitalization has begun to develop widely in recent years there is a notable lack of studies. The following study includes data from the Psychiatric Home Hospitalization Unit of the Hospital del Mar (HADMar). This program has been running for 2years and takes place in a socio-demographically depressed area in Barcelona. It receives patients from community and hospital services. Monitoring is limited in time and at discharge patient are referred to the ambulatory unit. Material and methods: All patients visited from 2015 to the present time were selected. A total of 135 patients were included in the sample. A qualitative descriptive study was carried out in order to define the socio-demographic characteristics. The severity of symptoms, suicidal risk and changes in the functionality were considered as clinical outcomes. Results: The mean age of patients was 44.6 years and there were no gender differences. A total of 26 patients had a history of suicidal attempts and 11.1% lived alone; 51.1% were diagnosed with a psychotic disorder. The mean GEP score for the severity of the psychiatric symptoms was 2.39 and the mean risk of suicide was 0.49. There is an increase in the EEAG score from admission to discharge, which means an improvement in the functionality of patients. Conclusions: The results obtained in our study are consistent with previous results. Home crisis intervention teams have proved to be an alternative to traditional hospitalization. However, more studies are needed to support these results
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Mental Disorders/therapy , Home Care Services, Hospital-Based/organization & administration , Psychotic Disorders/therapy , Severity of Illness Index , Suicidal Ideation , Epidemiology, Descriptive , Conduct Disorder/psychology , Community Mental Health Centers/organization & administration , Crisis Intervention/organization & administrationABSTRACT
INTRODUCTION: Although home hospitalization has begun to develop widely in recent years there is a notable lack of studies. The following study includes data from the Psychiatric Home Hospitalization Unit of the Hospital del Mar (HADMar). This program has been running for 2years and takes place in a socio-demographically depressed area in Barcelona. It receives patients from community and hospital services. Monitoring is limited in time and at discharge patient are referred to the ambulatory unit. MATERIAL AND METHODS: All patients visited from 2015 to the present time were selected. A total of 135 patients were included in the sample. A qualitative descriptive study was carried out in order to define the socio-demographic characteristics. The severity of symptoms, suicidal risk and changes in the functionality were considered as clinical outcomes. RESULTS: The mean age of patients was 44.6 years and there were no gender differences. A total of 26 patients had a history of suicidal attempts and 11.1% lived alone; 51.1% were diagnosed with a psychotic disorder. The mean GEP score for the severity of the psychiatric symptoms was 2.39 and the mean risk of suicide was 0.49. There is an increase in the EEAG score from admission to discharge, which means an improvement in the functionality of patients. CONCLUSIONS: The results obtained in our study are consistent with previous results. Home crisis intervention teams have proved to be an alternative to traditional hospitalization. However, more studies are needed to support these results.
Subject(s)
Crisis Intervention/statistics & numerical data , Home Care Services, Hospital-Based/statistics & numerical data , Mental Disorders/therapy , Suicide, Attempted/statistics & numerical data , Adult , After-Hours Care/organization & administration , Crisis Intervention/organization & administration , Educational Status , Female , Home Care Services, Hospital-Based/organization & administration , Humans , Male , Middle Aged , Program Evaluation , Socioeconomic Factors , Spain , Symptom AssessmentABSTRACT
Although various types of hallucinations are reported at high rates during childhood, the research focusing on visual hallucinations is relatively scarce.1 Visual hallucinations have often been linked to biological causes and have been considered uncommon in psychiatric samples. However, recent studies suggest that almost 30% of visual hallucinations occur in the context of psychosis.1 The risk of psychopathology is often a cause of concern when children report visual hallucinations, especially when associated with poor functioning. A detailed history must be taken to determine whether reported hallucinations are a phenomenon of typical development (for example, imaginary friends, or hypnopompic or hypnogogic hallucinations), a symptom of trauma or anxiety, or have another etiology. In the presence of confirmed distressing complex hallucinations, clinicians should clarify whether they are neurological in origin or are a symptom of an established psychiatric disorder.
Subject(s)
Epilepsy/diagnosis , Hallucinations/etiology , Occipital Lobe , Child , Electroencephalography , Epilepsy/drug therapy , Female , Humans , Psychiatric Department, Hospital , Valproic Acid/therapeutic useABSTRACT
BACKGROUND: Multiple sclerosis is a chronic disease considered the major cause of neurological disability in young adults worldwide. While depression is considered a determinant factor of impaired quality of life and poorer prognosis among patients with multiple sclerosis, it is very often dismissed and undertreated by physicians. Depression has been related to treatment with some immunomodulatory drugs, such as IFNß. Data from patients who committed suicide during the pivotal study of interferon used as a disease modifying treatment in multiple sclerosis support this association. Moreover, there is plenty of evidence of neuropsychiatric toxicity caused by the use of IFNα as a treatment for other medical conditions. Although this link still remains relatively unknown, the presence of warnings regarding the possible relationship between depression and IFNß led to restriction in medical indications in these patients. The purpose of this paper is to try to understand the reasons for an increased prevalence in depression in multiple sclerosis and to examine the impact that IFNß treatment has on their mood. METHODS: We performed a literature search on MEDLINE and Google Scholar databases applying PRISMA guidelines for systematic reviews. Studies were included if the participants were diagnosed with MS and prescribed IFNß as the main treatment. We excluded non-english and full-text non available papers, as well as the articles where mental health was assessed exclusively as a feature of quality of life. The sample includes articles from 1980 to 2014, although filtration by year of publication was not applied and contains data from IFNß-1a and IFNß-1b. The Cochrane Collaboration Tool assessing risk of bias was used to determine the quality of the studies. RESULTS: Ten studies met full criteria for inclusion and final data extraction. The articles have heterogeneity regarding the samples, the methodology used and the expression of the results. Only three studies support the evidence of a relationship between depression and interferon, which is statistically significant in some patients at the beginning of the treatment. They suggest that only patients on IFNß treatment with a past history of depression may develop a major depression episode during the first six months. The remaining articles reviewed (including BENEFIT, BEYOND, and LTF trials) suggest the absence of an association. CONCLUSION: The reviewed studies conclude that there is not a clear relationship between IFNß and depression. A history of depression is a risk factor for developing depression during the first 6 months of treatment, nevertheless, it is not sufficient to contraindicate it. The development of new strategies is crucial for early detection of depressive symptoms. An adequate treatment can both improve the mood and deal with the neurological disease by increasing treatment adherence and interfering with inflammation. Chronic destructive brain changes and serotonergic depletion due to inflammatory factors have been proposed as the underlying cause of depression in these patients. It is suggested that these patients would have fewer functional reserve remaining to deal with stressful life events, which could precipitate a depressive disorder.
Subject(s)
Depressive Disorder/complications , Immunologic Factors/therapeutic use , Interferon-beta/therapeutic use , Multiple Sclerosis/complications , Multiple Sclerosis/drug therapy , Depressive Disorder/physiopathology , Humans , Immunologic Factors/adverse effects , Interferon-beta/adverse effects , Multiple Sclerosis/physiopathology , Multiple Sclerosis/psychologyABSTRACT
La clozapina es el fármaco de primera elección en el manejo de la esquizofrenia resistente al tratamiento, y no existe ninguna alternativa terapéutica que haya demostrado mayor eficacia en estos pacientes. Por ello es importante optimizar el tratamiento con clozapina en la esquizofrenia resistente. Una de las herramientas clínicas de las que se dispone es la monitorización de los niveles plasmáticos del fármaco, ya que permite asegurar que el paciente está dentro del rango terapéutico y disminuye el riesgo de efectos adversos. La evidencia disponible concluye en establecer un límite inferior alrededor de los 350 ng/ml. Sin embargo, la cuestión del límite superior del intervalo es más compleja y no existe un acuerdo sobre la concentración sanguínea de clozapina que se asocia a toxicidad. Presentamos un caso clínico de un paciente con esquizofrenia resistente en tratamiento con clozapina, en el cual la monitorización de niveles plasmáticos pudo influir en las decisiones terapéuticas (AU)
Clozapine should be considered as first-line treatment in individuals with a diagnosed treatment-resistant schizophrenia. Despite alternative treatments and augmentation strategies available, there is no consistent evidence that none of these options produce substantive clinical gains when clozapine-treated patients demonstrate a suboptimal clinical response. It is therefore important that we optimize clozapine treatment in these patients. One of the clinical tools to assist in this has been therapeutic drug monitoring of plasmatic levels, because it provides drug concentrations associated with highest probability of response and a low risk of side effects. A number of studies have addressed the therapeutic range of clozapine's plasmatic level, and reviews of this topic have generally agreed that the lower threshold is around 350 ng/ml. In contrast, the issue of an upper threshold is more complex and there is no agreed for an upper limit associated with clozapine toxicity. We report a case of a patient with the diagnosis of treatment-resistant schizophrenia treated with clozapine in which we think that therapeutic drug monitoring of clozapine plasmatic could influence treatment decisions (AU)
Subject(s)
Adult , Humans , Male , Clozapine/blood , Schizophrenia, Paranoid/drug therapy , Clozapine/therapeutic use , Drug Resistance , Treatment OutcomeABSTRACT
No disponible
